尽管尚未获得任何监管机构批准，但瑞他鲁肽（retatrutide）可能有助于改善血糖水平并减轻炎症。
据此类药物中规模最大的研究，减重领域的‘哥斯拉’或能改善血糖、减轻炎症，并使人的体重减少四分之一。
Though not yet approved by any regulatory agency, retatrutide could help improve blood sugar levels and reduce inflammation The ‘Godzilla’ of weight-loss drugs could help improve blood sugar levels, reduce inflammation and cut a person’s body weight by a quarter, according to the largest study of its kind.
瑞他鲁肽可模拟三种有助于控制食欲、血糖和新陈代谢的关键肠道激素：GLP-1、GIP和胰高血糖素。
Retatrutide mimics three key gut hormones that help control appetite, blood sugar and metabolism: GLP-1, GIP and glucagon.
Wegovy等其他药物主要通过GLP-1通路抑制食欲，而Mounjaro含有GLP-1和GIP，用于控制血糖水平；与这些药物不同，瑞他鲁肽还会作用于胰高血糖素受体，从而帮助增加能量消耗。
Unlike other drugs such as Wegovy, which primarily targets the GLP-1 pathway to suppress appetite, or Mounjaro, which contains GLP-1 plus GIP to control blood sugar levels, retatrutide also engages the glucagon receptor, which helps increase energy expenditure.